AEON Clinic positions Dubai as global hub for longevity medicine with pioneering masterclass
With accreditation from both international authorities and the Dubai Health Authority (DHA), the event attracted over 150 medical professionals, researchers, and innovators from across the globe.
Attendees engaged in keynote sessions, case studies, and scientific workshops that explored cutting-edge treatments in age reversal, stem cell therapy, gene editing, mitochondrial medicine, immunotherapy, and photobiomodulation.
A convergence of global expertise
The masterclass featured presentations from more than 30 world-renowned experts, including Prof. David Barzilai, Prof. Brian Kennedy, Dr. Evelyne Bischof, Prof. Karim Nayernia, and Dr. Michael Weber. AEON Clinic's own medical team, including founder Dr. Jaffer Khan, joined the international faculty in showcasing the clinic's approach to integrating regenerative science with luxury patient care.
In addition to the main programme, 60 selected participants received exclusive hands-on training at Atlantis The Royal in specialised workshops ranging from facial harmony injectables and thread lifting to photobiomodulation and ozone therapy.
The event's thematic tracks reflected the broad scope of modern longevity science, including:
Regenerative Medicine & Advanced Therapeutics – exploring stem cells, gene editing, and CRISPR
Precision & Functional Medicine – using genomics and AI for predictive care
Longevity & Biological Age Reversal – diving into age-related biomarkers and lifestyle interventions
Neurodegenerative & Autoimmune Disorders – unveiling treatments for Parkinson's, Alzheimer's, and more
Regenerative Aesthetics – demonstrating protocols involving exosomes, threads, and photobiomodulation
Pharmacogenomics & Personalised Medicine – shaping the future of drug response analytics
By emphasising clinical translation, the masterclass aligned with AEON's mission to embed evidence-based, preventive healthcare practices in everyday clinical settings.
Influential participation and strategic support
In attendance were high-level figures from the Dubai Health Authority, including Dr. Younis Mohamed Kazim, CEO of the Health Regulation Sector, and Dr. Latifa Ahmad Al Rustamani, Director of Medical Education & Research. Other notable attendees included Dr. Mariam Mohamed Fatima Matar, Founder & Chairperson of the UAE Genetic Diseases Association, alongside senior executives from Atlantis Resorts.
The event was backed by strategic alliances with institutions such as the American Board of Regenerative Medicine, Geneva College of Longevity Science, and P7Medicine, positioning AEON as the only clinic in the Middle East affiliated with ABRM.
'This masterclass represents a shift – not only in the way we treat ageing and chronic disease but in how we educate, collaborate, and evolve as a medical community,' said Dr. Jaffer Khan, Founder of AEON Clinic.
Following the success of this inaugural event, AEON Clinic has announced plans to host the Next-Generation Medicine Masterclass annually, establishing Dubai as a central node in the global movement toward longevity-first, data-driven healthcare systems.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
17 minutes ago
- Khaleej Times
PureHealth reports Dh13.6 billion in revenue and Dh1.03 billion in net profit for H1
PureHealth Holding, the largest healthcare group in the Middle East, on Thursday announced a 9 per cent year-on-year revenue increase to Dh13.6 billion in H1 2025, driven by broad-based growth across both its healthcare and insurance verticals. Ebitda rose 8 per cent year-on-year to Dh2.3 billion in H1-2025, while net profit reached Dh1.03 billion, up 2 per cent year-on-year. As part of its continued evolution and transformation of acquired assets, PureHealth is streamlining its operating model built around two core verticals: Care and Cover. This structure brings together all Group businesses under each vertical, with 'Care' encompassing Hospitals, Procurement, Diagnostics, and Technology, while 'Cover' includes the Group's Insurance operations. Kamal Al Maazmi, Chairman of PureHealth, said: 'PureHealth's strong performance in the first half of 2025 reflects the profound ambition driving our transformation, building a global, future-ready healthcare ecosystem that is both technologically advanced and deeply human. By aligning innovation with national priorities and international partnerships, we are not only expanding access to care, but we are also reshaping how health is delivered, experienced, and sustained.' Shaista Asif, Group Chief Executive Officer at PureHealth, commented, 'We delivered solid growth in the first half of 2025 across both our Care and Cover verticals. Our entry into the Property & Casualty segment through Daman strengthens our ability to offer comprehensive, multi-line coverage. We continue to enhance our services through AI-powered solutions that make healthcare more intelligent and efficient. As we expand globally, our focus remains on synergies, transformation of the assets, and delivering better health outcomes within communities we operate.' The Care vertical was the largest contributor to revenue during the period, accounting for 72 per cent of the group's top-line at dh9.8 Billion in revenue, up 7 per cent year-on-year in h1 2025. This growth witnessed across several segments, including hospitals, diagnostics, and technology. Performance in UAE and UK was driven by a 13 per cent increase in outpatient volumes to 4.4 million visits, and a 7 per cent rise in inpatient volumes to 108,000 visits across the Hospitals vertical. In the UAE, this growth was supported by expanded service offerings, increased specialist capacity, and growing demand across SEHA and SSMC networks. In the UK, Circle Health saw increased patient volumes and further strengthened its position through the successful bolt on acquisition of Fairfield Independent Hospital in the Merseyside. The acquisition will expand inpatient capacity and available medical staff, which will ultimately support Circle Health's continued growth in high-demand regions. While Procurement revenue decreased 5 per cent year-on-year to Dh2.6 billion in H1 2025, Rafed has continued expansion of its supplier network. Its recent appointed role as the exclusive distributor for the Abu Dhabi government's Unified Purchasing Programme, has since strengthened its position as a central enabler within the Group's healthcare delivery model. PureLab recorded a 19 per cent year-on-year increase in total testing volume, reaching 16.9 million tests. This strong performance was largely fuelled by enhanced contributions from SEHA and the successful integration of the SSMC laboratory into the PureLab network. The Technology Services reported exceptional growth, with revenue increasing 170 per cent year-on-year to Dh367 million in H1-2025. This was driven by the continued expansion of PureCS, which deployed digital infrastructure and clinical technology solutions across the Group's entities. The Pura app surpassed 620,000 users during the period, while the Group's broader technology backbone is enabling predictive analytics, digital patient engagement, and AI-enhanced care delivery. The Cover vertical revenue increased 14 per cent year-on-year to Dh3.8 billion, supported by an 8 per cent rise in Gross Written Premiums (GWP) to Dh4.9 billion in H1-2025. Growth was further fuelled by new business, driven by expansion into underpenetrated segments and geographies. Membership increased 6 per cent year-on-year, reflecting the Group's compelling value proposition and strong customer retention. PureHealth's balance sheet remains strong, with a Net Debt to Ebitda ratio of 1.4x, providing the Group with ample flexibility to pursue future M&A opportunities and invest in strategic organic growth initiatives across its global healthcare platform. PureHealth repaid Dh1.85 billion in bank debt ahead of its 2027 maturity and currently has no bank debt.
Khaleej Times
17 minutes ago
- Khaleej Times
Response Plus Holding reports Dh248 million revenue in H1
Response Plus Holding PJSC, the largest pre-hospital care and emergency medical services provider in the UAE and KSA, has achieved revenue of Dh248.06 million in the first six months of 2025, a growth of 18% compared to Dh209.88 million recorded in the same period last year. Announcing the company's interim financial results for the first half of 2025, RPM registered net profit of Dh20.32 million, while total assets touched Dh404.32 million, up from Dh387.44 million as of December 31, 2024, reflecting continued balance sheet strength and sustained investment momentum. The Earnings Per Share (EPS) for the period was Dh0.10. As part of its commitment to deliver shareholder value, the Board of Directors has approved an interim cash dividend distribution of Dh18 million to the shareholders. Dr Rohil Raghavan, Chief Executive Officer of Response Plus Holding, said: 'The first half of 2025 reflects our strategic agility and continued investment in excellence. From expanding into new geographies to launching the first-of-its-kind services in the region, we are driving impactful growth while prioritizing operational efficiencies. With a strong foundation and forward-looking initiatives, we are well-positioned to deliver greater value to our clients, partners, and shareholders.' RPM delivered strategic milestones during the first half of 2025, reinforcing its leadership in regional and global emergency medical care. The company expanded its aviation emergency operations to The Bahamas, demonstrating its capabilities to scale internationally while enhancing its disaster and air evacuation readiness. During the Hajj season, the company deployed 350 medical professionals and 125 ambulances in 18 clinics across nine stations of Saudi Arabia Railways to support millions of pilgrims visiting the Holy sites. RPM also signed a MoU with Falcon Aviation to operate the UAE's first air ambulance service, a landmark step in enhancing the country's emergency response infrastructure. RPM currently operates over 420 medical sites through key subsidiaries including Prometheus Medical, Occumed Clinic, Health Tech Training Centre, and Medical Manpower Supply. With operations spanning the UAE, KSA, Oman, India, the UK, Switzerland, and Norway, RPM remains firmly committed to redefining the future of pre-hospital emergency medical services.
Zawya
7 hours ago
- Zawya
Mayo Clinic discovery could mean better access to more donor hearts and improved transplant outcomes
Dubai, United Arab Emirates — A new discovery by Mayo Clinic researchers could mean more donor hearts are available for heart transplant, giving more people a second chance at life. In findings published in Nature Cardiovascular Research, a team led by Mayo Clinic cardiac surgeon Paul Tang, M.D., Ph.D., identified a biological process that contributes to donor heart injury during cold storage. The researchers found that a drug already used to treat heart conditions can prevent this damage. Heart transplantation is the most effective treatment for end-stage heart failure, yet fewer than half of donor hearts are ultimately used. One major reason is the relatively short window for transplanting a donated heart into a patient, due to concerns over low donor heart function that comes from leaving a heart in cold storage too long. Why donor hearts deteriorate in cold storage Although cold storage slows metabolism and helps preserve tissue, prolonged exposure to cold storage conditions can lead to molecular changes that compromise how well the heart performs after transplant. One complication is called primary graft dysfunction, in which the transplanted heart cannot pump blood effectively after surgery. This may affect up to 20% of recipients to varying degrees. To investigate why this damage occurs, the researchers focused on a protein inside heart cells called the mineralocorticoid receptor, which plays a role in how cells respond to stress. During cold storage, they found that this protein undergoes a process in which the protein clumps together in a way that harms the heart cells, called liquid-liquid phase separation. This process promotes cardiac damage from increased inflammation and cell death, making the heart less likely to function well after transplant. Preventing damage with a common drug To test whether the process could be prevented, the researchers treated donor hearts with a drug called canrenone, which blocks mineralocorticoid receptor activity. In human donor hearts stored beyond the typical timeframe, treatment with the drug nearly tripled their pumping strength compared to hearts stored without it. The hearts also showed better blood flow and fewer signs of cell injury. The findings suggest canrenone may help extend the safe storage period for donor hearts by improving the heart's pumping strength to increase chances of a successful transplant. "As a cardiovascular surgeon, I've personally experienced in the operating room how every additional hour of preservation can impact the likelihood of whether a donor heart can return to normal function after transplantation," Dr. Tang says. "This discovery may give us a new tool to preserve heart function for longer during storage, improve transplant outcomes and enhance patient access to lifesaving transplants." The study's findings also have the potential to improve the preservation of other transplantable organs. Similar protein clustering was observed in donor kidneys, lungs and livers during cold storage. This suggests that the same strategy may help expand transplant options across multiple organ systems.
